| Autor: |
Hornung LB; Viro-Immunology Research Unit, Department of Infectious Diseases, Copenhagen University Hospital-Rigshospitalet, 2100 Copenhagen, Denmark., Hamm SR; Viro-Immunology Research Unit, Department of Infectious Diseases, Copenhagen University Hospital-Rigshospitalet, 2100 Copenhagen, Denmark., Hald A; Viro-Immunology Research Unit, Department of Infectious Diseases, Copenhagen University Hospital-Rigshospitalet, 2100 Copenhagen, Denmark., Harboe ZB; Department of Pulmonary and Infectious Diseases, Copenhagen University Hospital-North Zealand, 3400 Hillerød, Denmark.; Department of Clinical Medicine, University of Copenhagen, 2200 Copenhagen, Denmark., Lundbo LF; Department of Infectious Diseases, Copenhagen University Hospital-Rigshospitalet, 2100 Copenhagen, Denmark., Wareham NE; Department of Infectious Diseases, Copenhagen University Hospital-Rigshospitalet, 2100 Copenhagen, Denmark., Heftdal LD; Viro-Immunology Research Unit, Department of Infectious Diseases, Copenhagen University Hospital-Rigshospitalet, 2100 Copenhagen, Denmark., Ekenberg C; Department of Infectious Diseases, Copenhagen University Hospital-Rigshospitalet, 2100 Copenhagen, Denmark., Bjerrum S; Department of Infectious Diseases, Copenhagen University Hospital-Rigshospitalet, 2100 Copenhagen, Denmark., Holler JG; Department of Infectious Diseases, Copenhagen University Hospital-Rigshospitalet, 2100 Copenhagen, Denmark., Mathiesen IHM; Department of Infectious Diseases, Copenhagen University Hospital-Rigshospitalet, 2100 Copenhagen, Denmark., Krohn PS; Department of Surgical Gastroenterology and Transplantation, Copenhagen University Hospital-Rigshospitalet, 2100 Copenhagen, Denmark., Bjerring PN; Department of Clinical Medicine, University of Copenhagen, 2200 Copenhagen, Denmark.; Department of Intestinal Failure and Liver Diseases, Copenhagen University Hospital-Rigshospitalet, 2100 Copenhagen, Denmark., Gustafsson F; Department of Clinical Medicine, University of Copenhagen, 2200 Copenhagen, Denmark.; Department of Cardiology, Heart and Lung Transplant Unit, Copenhagen University Hospital-Rigshospitalet, 2100 Copenhagen, Denmark., Perch M; Department of Clinical Medicine, University of Copenhagen, 2200 Copenhagen, Denmark.; Department of Cardiology, Heart and Lung Transplant Unit, Copenhagen University Hospital-Rigshospitalet, 2100 Copenhagen, Denmark., Rasmussen A; Department of Surgical Gastroenterology and Transplantation, Copenhagen University Hospital-Rigshospitalet, 2100 Copenhagen, Denmark., Nielsen SD; Viro-Immunology Research Unit, Department of Infectious Diseases, Copenhagen University Hospital-Rigshospitalet, 2100 Copenhagen, Denmark.; Department of Clinical Medicine, University of Copenhagen, 2200 Copenhagen, Denmark.; Department of Surgical Gastroenterology and Transplantation, Copenhagen University Hospital-Rigshospitalet, 2100 Copenhagen, Denmark. |
| Abstrakt: |
Vaccination before solid organ transplantation is recommended since post-transplantation immunosuppression is known to impair vaccine responses. However, little is known about post-transplantation seroprotection rates in organ transplant recipients vaccinated pre-transplantation. We aimed to investigate the proportion of transplant recipients vaccinated against hepatitis B virus (HBV) and invasive pneumococcal disease (IPD) pre-transplantation at the time of listing for transplantation with post-transplantation seroprotection. We included 136 solid organ transplant (SOT) recipients vaccinated at the time of listing for transplantation. We investigated post-transplantation antibody concentrations against HBV and IPD. Established antibody thresholds were used to define seroprotection. The proportions of SOT recipients with post-transplantation seroprotection were 27.9% ( n = 38) and 42.6% ( n = 58) against HBV and IPD, respectively. Compared to completing HBV vaccination pre-transplantation, completing post-transplantation vaccination (adjusted odds ratio (aOR): 7.8, 95% CI: 2.5-24.5, p < 0.001) and incomplete vaccination (aOR: 6.3, 95% CI: 1.2-32.6, p = 0.028) were associated with non-response against HBV, after adjustment for confounders. Importantly, patients with seroprotection at the time of listing had lower odds of non-response against HBV (aOR: 0.04, 95% CI: 0.0-0.1, p < 0.001) and IPD (aOR: 0.3, 95% CI: 0.1-0.7, p = 0.007) compared to those without seroprotection. SOT recipients vaccinated pre-transplantation had low post-transplantation seroprotection rates against HBV and IPD. However, SOT recipients with seroprotection at the time of listing had lower odds of non-response, suggesting early vaccination should be a priority. |
